日本医科大学 消化器内科学での、食道、胃、十二指腸、小腸、大腸、肝臓、胆嚢、膵臓といった消化器に関する研究活動の業績をご紹介します。

消化器内科学のご紹介

患者さまへ

医師・医療機関の方々へ

研修医の皆様へ

日本医科大学グループサイトへ

トップページ > 消化器内科学のご紹介 研究業績

研究業績

英文主要論文(2012-2017)

  • 1 Atsukawa M, Tsubota A, Kondo C, Shimada N, Abe H, Kato K, Okubo T, Arai T, Itokawa N, Iio E, Tanaka Y, Iwakiri K. Effectiveness and safety of community-based treatment with sofosbuvir plus ribavirin for elderly patients with genotype 2 chronic hepatitis C. Dig Liver Dis. in Press.
  • 2 Atsukawa M, Tsubota A, Koushima Y, Ikegami T, Watanabe K, Shimada N, Sato S, Kato K, Abe H, Okubo T, Arai T, Itokawa N, Kondo C, Mikami S, Asano T, Chuganji Y, Matsuzaki Y, Iwakiri K. Efficacy and safety of ombitasvir/paritaprevir/ritonavir in dialysis patients with genotype 1b chronic hepatitis C. Hepatol Res. in Press.
  • 3 Iio E, Shimada N, Takaguchi K, Senoh T, Eguchi Y, Atsukawa M, Tsubota A, Abe H, Kato K, Kusakabe A, Miyaki T, Matsuura K, Matsunami K, Shinkai N, Fujiwara K, Nojiri S, Tanaka Y. Clinical evaluation of sofosbuvir/ledipasvir in patients with chronic hepatitis C genotype 1 with and without prior daclatasvir/asunaprevir therapy. Hepatol Res. in Press.
  • 4 Hoshino S, Kawami N, Takenouchi N, Umezawa M, Hanada Y, Hoshikawa Y, Kawagoe T, Sano H, Hoshihara Y, Nomura T, Iwakiri K. Efficacy of Vonoprazan for Proton Pump Inhibitor-Resistant Reflux Esophagitis. Digestion. 2017;95:156-161.
  • 5 Kawami N, Takenouchi N, Umezawa M, Hoshino S, Hanada Y, Hoshikawa Y, Sano H, Hoshihara Y, Nomura T, Uchida E, Iwakiri K. Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection. Digestion. 2017;95:140-145.
  • 6 Hoshino S, Takenouchi N, Hanada Y, Umezawa M, Sano H, Kawami K, Hoshikawa Y, Kawagoe T, Nomura T, Hoshihara Y, Iwakiri K. Effects of acotiamide on esophageal motility in healthy subjects: a randomized, double-blind, placebo-controlled crossover study. Esophagus 2017;14:146-52.
  • 7 Kondo C., Atsukawa M., Tsubota A., Shimada N., Abe H., Asano T., Yoshizawa K., Okubo T., Chuganji Y., Aizawa Y., Iio E., Tanaka Y., Iwakiri K. Daclatasvir and asunaprevir for genotype 1b chronic hepatitis C patients with chronic kidney disease. Hepatol Res 2017.
  • 8 Iio E., Shimada N., Abe H., Atsukawa M., Yoshizawa K., Takaguchi K., Eguchi Y., Nomura H., Kuramitsu T., Kang J. H., Matsui T., Hirashima N., Tsubota A., Kusakabe A., Hasegawa I., Miyaki T., Shinkai N., Fujiwara K., Nojiri S., Tanaka Y. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol 2017;52:94-103.
  • 9 Yamawaki H., Futagami S., Kawagoe T., Maruki Y., Hashimoto S., Nagoya H., Sato H., Kodaka Y., Gudis K., Akamizu T., Sakamoto C., Iwakiri K. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil 2016;28:1037-47.
  • 10 Tari A., Asaoku H., Takata K., Fujimori S., Tanaka S., Fujihara M., Koga T., Yoshino T. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era. Scand J Gastroenterol 2016;51:321-8.
  • 11 Shoji H., Yoshio S., Mano Y., Kumagai E., Sugiyama M., Korenaga M., Arai T., Itokawa N., Atsukawa M., Aikata H., Hyogo H., Chayama K., Ohashi T., Ito K., Yoneda M., Nozaki Y., Kawaguchi T., Torimura T., Abe M., Hiasa Y., Fukai M., Kamiyama T., Taketomi A., Mizokami M., Kanto T. Interleukin-34 as a fibroblast-derived marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:28814.
  • 12 Okubo T., Atsukawa M., Tsubota A., Shimada N., Abe H., Yoshizawa K., Arai T., Nakagawa A., Itokawa N., Kondo C., Aizawa Y., Iwakiri K. Association between vitamin D deficiency and pre-existing resistance-associated hepatitis C virus NS5A variants. Hepatol Res 2016.
  • 13 Nakagawa A., Atsukawa M., Tsubota A., Kondo C., Okubo T., Arai T., Itokawa N., Narahara Y., Iwakiri K. Usefulness of portal vein pressure for predicting the effects of tolvaptan in cirrhotic patients. World J Gastroenterol 2016;22:5104-13.
  • 14 Mitsui K., Fujimori S., Tanaka S., Ehara A., Omori J., Akimoto N., Maki K., Suzuki M., Kosugi Y., Ensaka Y., Matsuura Y., Kobayashi T., Yonezawa M., Tatsuguchi A., Sakamoto C. Retrieval of Retained Capsule Endoscopy at Small Bowel Stricture by Double-Balloon Endoscopy Significantly Decreases Surgical Treatment. J Clin Gastroenterol 2016;50:141-6.
  • 15 Kumagai E., Mano Y., Yoshio S., Shoji H., Sugiyama M., Korenaga M., Ishida T., Arai T., Itokawa N., Atsukawa M., Hyogo H., Chayama K., Ohashi T., Ito K., Yoneda M., Kawaguchi T., Torimura T., Nozaki Y., Watanabe S., Mizokami M., Kanto T. Serum YKL-40 as a marker of liver fibrosis in patients with non-alcoholic fatty liver disease. Sci Rep 2016;6:35282.
  • 16 Kondo C., Atsukawa M., Tsubota A., Shimada N., Abe H., Aizawa Y. Evaluation of factors associated with relapse in telaprevir-based triple therapy for chronic hepatitis C. J Postgrad Med 2016;62:20-5.
  • 17 Kawamura O., Kohata Y., Kawami N., Iida H., Kawada A., Hosaka H., Shimoyama Y., Kuribayashi S., Fujiwara Y., Iwakiri K., Inamori M., Kusano M., Hongo M. Liquid-containing Refluxes and Acid Refluxes May Be Less Frequent in the Japanese Population Than in Other Populations: Normal Values of 24- hour Esophageal Impedance and pH Monitoring. J Neurogastroenterol Motil 2016;22:620-629.
  • 18 Kawagoe T., Maruki Y., Nagoya H., Kosugi Y., Akimoto T., Yamawaki H., Kodaka Y., Shimpuku M., Ueki N., Futagami S., Miyake K., Iwakiri K. Clinical Complete Response from Chemotherapy in an Elderly Patient with Metastatic Gastric Cancer: A Case Report. J Nippon Med Sch 2016;83:199-202.
  • 19 Iwakiri K., Kinoshita Y., Habu Y., Oshima T., Manabe N., Fujiwara Y., Nagahara A., Kawamura O., Iwakiri R., Ozawa S., Ashida K., Ohara S., Kashiwagi H., Adachi K., Higuchi K., Miwa H., Fujimoto K., Kusano M., Hoshihara Y., Kawano T., Haruma K., Hongo M., Sugano K., Watanabe M., Shimosegawa T. Evidence-based clinical practice guidelines for gastroesophageal reflux disease 2015. J Gastroenterol 2016;51:751-67.
  • 20 Itokawa N., Atsukawa M., Tsubota A., Okubo T., Arai T., Nakagawa A., Kondo C., Iwakiri K. Effects of sorafenib combined with low-dose interferon therapy for advanced hepatocellular carcinoma: a pilot study. Int J Clin Oncol 2016;21:676-83.
  • 21 Ichiyama S., Matayoshi T., Kaneko T., Shimizu A., Osada S. I., Watanabe A., Kanzaki A., Mitsui K., Tsuruoka S., Iwakiri K., Kawana S., Saeki H. Successful multitarget therapy using prednisolone, mizoribine and tacrolimus for Henoch-Schonlein purpura nephritis in children. J Dermatol 2016.
  • 22 Futagami S., Yamawaki H., Hashimoto S., Iwakiri K. Sleep Disturbances in Functional Gastrointestinal Disorders. Intern Med 2016;55:1509-10.
  • 23 Fujita T., Waga E., Kitaoka K., Imagawa T., Komatsu Y., Takanashi K., Anbo F., Anbo T., Katuki S., Ichihara S., Fujimori S., Yamasaki H., Morishima Y., Sugiyama H., Katahira H. Human infection by acanthocephalan parasites belonging to the genus Corynosoma found from small bowel endoscopy. Parasitol Int 2016;65:491-3.
  • 24 Fujimori S., Hanada R., Hayashida M., Sakurai T., Ikushima I., Sakamoto C. Celecoxib Monotherapy Maintained Small Intestinal Mucosa Better Compared With Loxoprofen Plus Lansoprazole Treatment: A Double-blind, Randomized, Controlled Trial. J Clin Gastroenterol 2016;50:218-26.
  • 25 Atsukawa M., Tsubota A., Shimada N., Yoshizawa K., Abe H., Asano T., Ohkubo Y., Araki M., Ikegami T., Okubo T., Kondo C., Osada Y., Nakatsuka K., Chuganji Y., Matsuzaki Y., Iwakiri K., Aizawa Y. Effect of native vitamin D3 supplementation on refractory chronic hepatitis C patients in simeprevir with pegylated interferon/ribavirin. Hepatol Res 2016;46:450-8.
  • 26 Ashida K., Sakurai Y., Hori T., Kudou K., Nishimura A., Hiramatsu N., Umegaki E., Iwakiri K. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis. Aliment Pharmacol Ther 2016;43:240-51.
  • 27 Yamawaki H., Futagami S., Shimpuku M., Shindo T., Maruki Y., Nagoya H., Kodaka Y., Sato H., Gudis K., Kawagoe T., Sakamoto C. Leu72Met408 Polymorphism of the Ghrelin Gene Is Associated With Early Phase of Gastric Emptying in the Patients With Functional Dyspepsia in Japan. J Neurogastroenterol Motil 2015;21:93-102.
  • 28 Nomura T., Iwakiri K., Matsutani T., Hagiwara N., Fujita I., Nakamura Y., Kawami N., Miyashita M., Uchida E. Thoracoscopic long myotomy in the prone position to treat rapid esophageal contractions with normal latency. J Clin Gastroenterol 2015;49:320-2.
  • 29 Miyake K., Akimoto T., Hanada Y., Nagoya H., Kodaka Y., Ueki N., Kusunoki M., Kawagoe T., Futagami S., Takahashi Y., Takano H., Sakamoto C. Proton pump inhibitors are associated with lower gastrointestinal tract bleeding in low-dose aspirin users with ischaemic heart disease. Dig Liver Dis 2015;47:757-62.
  • 30 Kondo C., Atsukawa M., Tsubota A., Shimada N., Abe H., Itokawa N., Nakagawa A., Fukuda T., Matsushita Y., Nakatsuka K., Kawamoto C., Iwakiri K., Aizawa Y., Sakamoto C. Safety and efficacy of partial splenic embolization in telaprevir-based triple therapy for chronic hepatitis C. Intern Med 2015;54:119-26.
  • 31 Kawami N., Iwakiri K., Sano H., Tanaka Y., Sakamoto C. Effects of aging and acid reflux on esophageal motility. Digestion 2015;91:181-6.
  • 32 Futagami S., Itoh T., Sakamoto C. Systematic review with meta-analysis: post-infectious functional dyspepsia. Aliment Pharmacol Ther 2015;41:177-88.
  • 33 Fujimori S. What are the effects of proton pump inhibitors on the small intestine? World J Gastroenterol 2015;21:6817-9.
  • 34 Atsukawa M., Tsubota A., Shimada N., Yoshizawa K., Abe H., Asano T., Ohkubo Y., Araki M., Ikegami T., Kondo C., Itokawa N., Nakagawa A., Arai T., Matsushita Y., Nakatsuka K., Furihata T., Chuganji Y., Matsuzaki Y., Aizawa Y., Iwakiri K. Influencing factors on serum 25-hydroxyvitamin D3 levels in Japanese chronic hepatitis C patients. BMC Infect Dis 2015;15:344.
  • 35 Ashida K., Sakurai Y., Nishimura A., Kudou K., Hiramatsu N., Umegaki E., Iwakiri K., Chiba T. Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis. Aliment Pharmacol Ther 2015;42:685-95.
  • 36 Arai T., Atsukawa M., Tsubota A., Kondo C., Shimada N., Abe H., Itokawa N., Nakagawa A., Okubo T., Aizawa Y., Iwakiri K. Vitamin D-related gene polymorphisms do not influence the outcome and serum vitamin D level in pegylated interferon/ribavirin therapy combined with protease inhibitor for patients with genotype 1b chronic hepatitis C. J Med Virol 2015;87:1904-12.
  • 37 Yamawaki H., Futagami S., Shimpuku M., Sato H., Wakabayashi T., Maruki Y., Kodaka Y., Nagoya H., Shindo T., Kawagoe T., Sakamoto C. Impact of sleep disorders, quality of life and gastric emptying in distinct subtypes of functional dyspepsia in Japan. J Neurogastroenterol Motil 2014;20:104-12.
  • 38 Tsubota A., Shimada N., Atsukawa M., Abe H., Kato K., Ika M., Matsudaira H., Nagatsuma K., Matsuura T., Aizawa Y. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. J Gastroenterol Hepatol 2014;29:144-50.
  • 39 Taki Y., Kanazawa H., Narahara Y., Itokawa N., Kondo C., Fukuda T., Harimto H., Matsushita Y., Kidokoro H., Katakura T., Atsukawa M., Kimura Y., Nakatsuka K., Sakamoto C. Predictive factors for improvement of ascites after transjugular intrahepatic portosystemic shunt in patients with refractory ascites. Hepatol Res 2014;44:871-7.
  • 40 Shimpuku M., Futagami S., Tajima N., Yamawaki H., Maruki Y., Kodaka Y., Nagoya H., Gudis K., Kawagoe T., Sakamoto C. Impact of eating attitude and impairment of physical quality of life between tertiary clinic and primary clinic functional dyspepsia outpatients in Japan. J Neurogastroenterol Motil 2014;20:506-15.
  • 41 Sano H., Iwakiri K., Kawami N., Tanaka Y., Sakamoto C. Mechanisms of acid reflux and how refluxed Acid extends proximally in patients with non-erosive reflux disease. Digestion 2014;90:108-15.
  • 42 Nomura T., Iwakiri K., Uchida E. Thoracoscopic treatment of a patient with jackhammer esophagus. Dig Endosc 2014;26:753-4.
  • 43 Nakagawa A., Atsukawa M., Tsubota A., Shimada N., Abe H., Kondo C., Itokawa N., Arai T., Hashimoto S., Matsushita Y., Fukuda T., Nakatsuka K., Iwakiri K., Kawamoto C., Aizawa Y., Sakamoto C. Relationship between HCV dynamics and sustained virological responses in chronic hepatitis C genotype 1b patients treated with telaprevir-based triple therapy. Eur J Gastroenterol Hepatol 2014;26:1329-34.
  • 44 Mitsui K., Yonezawa M., Tatsuguchi A., Shinji S., Gudis K., Tanaka S., Fujimori S., Sakamoto C. Localization of phosphorylated ErbB1-4 and heregulin in colorectal cancer. BMC Cancer 2014;14:863.
  • 45 Li M., Omi T., Matano Y., Fujimori S., Kawana S. The diagnostic usefulness of video capsule endoscopy in adolescent immunoglobulin A vasculitis (Henoch-Schonlein purpura). J Nippon Med Sch 2014;81:114-7.
  • 46 Kikuchi K., Akiba T., Nitta K., Masakane I., Ando R., Izumi N., Atsukawa M., Yamazaki C., Kato F., Hotta N., Tominaga Y., Orito E., Hora K., Nagasawa M., Kasahara H., Kawaguchi M., Kimura H., Ikebe N., Kawanishi H., Moriishi M., Shigemoto K., Harada T., Hirakata H., Watanabe H., Nosaki T., Tsubouchi H., Imawari M., Akizawa T. Multicenter study of pegylated interferon alpha-2a monotherapy for hepatitis C virus-infected patients on hemodialysis: REACH study. Ther Apher Dial 2014;18:603-11.
  • 47 Kawaguchi I., Kamae I., Soen S., Sakamoto C. Cost-Effectiveness Analysis of Celecoxib In the Treatment of Patients With Chronic Pain In Japan. Value Health 2014;17:A533.
  • 48 Furuta K., Kohata Y., Fujiwara Y., Sugimoto M., Uotani T., Yamade M., Sahara S., Ichikawa H., Furuta T., Nio K., Iwakiri R., Inamori M., Kawamura O., Kusano M., Kato M., Kawami N., Iwakiri K., Takeuchi T., Higuchi K., Aimi M., Naora K., Fujimoto K., Arakawa T., Kinoshita Y. Intra-gastric pH following single oral administrations of rabeprazole and esomeprazole: double-blind cross-over comparison. J Clin Biochem Nutr 2014;55:178-83.
  • 49 Fukuda T., Narahara Y., Kanazawa H., Matsushita Y., Kidokoro H., Itokawa N., Kondo C., Atsukawa M., Nakatsuka K., Sakamoto C. Effects of fasudil on the portal and systemic hemodynamics of patients with cirrhosis. J Gastroenterol Hepatol 2014;29:325-9.
  • 50 Fujimori S., Takahashi Y., Tatsuguchi A., Sakamoto C. Omeprazole increased small intestinal mucosal injury in two of six disease-free cases evaluated by capsule endoscopy. Dig Endosc 2014;26:676-9.
  • 51 Atsukawa M., Tsubota A., Shimada N., Kondo C., Itokawa N., Nakagawa A., Hashimoto S., Fukuda T., Matsushita Y., Narahara Y., Iwakiri K., Nakatsuka K., Kawamoto C., Sakamoto C. Serum 25-hydroxyvitamin D3 levels affect treatment outcome in pegylated interferon/ribavirin combination therapy for compensated cirrhotic patients with hepatitis C virus genotype 1b and high viral load. Hepatol Res 2014;44:1277-85.
  • 52 Atsukawa M., Tsubota A., Shimada N., Kondo C., Itokawa N., Nakagawa A., Fukuda T., Matsushita Y., Narahara Y., Osada Y., Yamaguchi H., Nakatsuka K., Iwakiri K., Kawamoto C., Sakamoto C. Effect of fluvastatin on 24-week telaprevir-based combination therapy for hepatitis C virus genotype 1b-infected chronic hepatitis C. Eur J Gastroenterol Hepatol 2014;26:781-7.
  • 53 Atsukawa M., Tsubota A., Shimada N., Abe H., Kondo C., Itokawa N., Nakagawa A., Iwakiri K., Kawamoto C., Aizawa Y., Sakamoto C. Serum 25(OH)D3 levels affect treatment outcomes for telaprevir/peg-interferon/ribavirin combination therapy in genotype 1b chronic hepatitis C. Dig Liver Dis 2014;46:738-43.
  • 54 Abe H., Tsubota A., Shimada N., Atsukawa M., Kato K., Takaguchi K., Asano T., Chuganji Y., Sakamoto C., Toyoda H., Kumada T., Ide T., Sata M., Aizawa Y. Predictors of response to 24-week telaprevir-based triple therapy for treatment-naive genotype 1b chronic hepatitis C patients. Gastroenterol Res Pract 2014;2014:549709.
  • 55 Tanaka T., Ichikawa K., Maruoka T., Tomita S., Ueda H., Yamaguchi T., Shida Y., Kato H., Nagata H., Kubota K., Akimoto N., Sakamoto C., Imura J., Arita M., Tanaka H., Okamoto Y., Igarashi Y., Fujimori T. Analysis of the anatomic subsites, gender and age in unresectable advanced colorectal carcinomas in Tochigi, Japan suggests a shift in location towards the right side colon in elderly patients treated with cetuximab. Mol Clin Oncol 2013;1:291-296.
  • 56 Suzuki H., Kusunoki H., Kamiya T., Futagami S., Yamaguchi Y., Nishizawa T., Iwasaki E., Matsuzaki J., Takahashi S., Sakamoto C., Haruma K., Joh T., Asakura K., Hibi T. Effect of lansoprazole on the epigastric symptoms of functional dyspepsia (ELF study): A multicentre, prospective, randomized, double-blind, placebo-controlled clinical trial. United European Gastroenterol J 2013;1:445-52.
  • 57 Song J., Futagami S., Nagoya H., Kawagoe T., Yamawaki H., Kodaka Y., Tatsuguchi A., Gudis K., Wakabayashi T., Yonezawa M., Shimpuku M., Watarai Y., Iwakiri K., Hoshihara Y., Makino H., Miyashita M., Tsuchiya S., Li Y., S E. Crowe, Sakamoto C. Apurinic/apyrimidinic endonuclease-1 (APE-1) is overexpressed via the activation of NF-kappaB-p65 in MCP-1-positive esophageal squamous cell carcinoma tissue. J Clin Biochem Nutr 2013;52:112-9.
  • 58 Sakamoto C., Kawai T., Nakamura S., Sugioka T., Tabira J. Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther 2013;37:346-54.
  • 59 Miyake K., Kusunoki M., Ueki N., Yamada A., Nagoya H., Kodaka Y., Shindo T., Kawagoe T., Gudis K., Futagami S., Tsukui T., Sakamoto C. Classification of patients who experience a higher distress level to transoral esophagogastroduodenoscopy than to transnasal esophagogastroduodenoscopy. Dig Endosc 2013;25:397-405.
  • 60 Miyake K., Kusunoki M., Ueki N., Nagoya H., Kodaka Y., Shindo T., Kawagoe T., Gudis K., Futagami S., Tsukui T., Nakamura H., Sakamoto C. Implication of antithrombotic agents on potential bleeding from endoscopically determined peptic ulcers, incidentally detected as surrogate markers for nsaids-associated ulcers complication. Dig Endosc 2013;25:25-31.
  • 61 Miyake K., Akimoto T., Kusakabe M., Sato W., Yamada A., Yamawaki H., Kodaka Y., Shinpuku M., Nagoya H., Shindo T., Ueki N., Kusunoki M., Kawagoe T., Futagami S., Tsukui T., Sakamoto C. Water-soluble vitamin deficiencies in complicated peptic ulcer patients soon after ulcer onset in Japan. J Nutr Sci Vitaminol (Tokyo) 2013;59:503-8.
  • 62 Matsushita Y., Narahara Y., Fujimori S., Kanazawa H., Itokawa N., Fukuda T., Takahashi Y., Kondo C., Kidokoro H., Atsukawa M., Nakatsuka K., Sakamoto C. Effects of transjugular intrahepatic portosystemic shunt on changes in the small bowel mucosa of cirrhotic patients with portal hypertension. J Gastroenterol 2013;48:633-9.
  • 63 Itokawa N., Atsukawa M., Tsubota A., Kondo C., Hashimoto S., Fukuda T., Matsushita Y., Kidokoro H., Kobayashi T., Narahara Y., Nakatsuka K., Kanazawa H., Iwakiri K., Sakamoto C. Lead-in treatment with interferon-beta/ribavirin may modify the early hepatitis C virus dynamics in pegylated interferon alpha-2b/ribavirin combination for chronic hepatitis C patients with the IL28B minor genotype. J Gastroenterol Hepatol 2013;28:443-9.
  • 64 Harimoto H., Shimizu M., Nakagawa Y., Nakatsuka K., Wakabayashi A., Sakamoto C., Takahashi H. Inactivation of tumor-specific CD8(+) CTLs by tumor-infiltrating tolerogenic dendritic cells. Immunol Cell Biol 2013;91:545-55.
  • 65 Futagami S., Yamawaki H., Shimpuku M., Izumi N., Wakabayashi T., Kodaka Y., Nagoya H., Shindo T., Kawagoe T., Sakamoto C. Impact of coexisting irritable bowel syndrome and non-erosive reflux disease on postprandial abdominal fullness and sleep disorders in functional dyspepsia. J Nippon Med Sch 2013;80:362-70.
  • 66 Futagami S., Yamawaki H., Izumi N., Shimpuku M., Kodaka Y., Wakabayashi T., Nagoya H., Shindo T., Kawagoe T., Gudis K., Itoh T., Sakamoto C. Impact of sleep disorders in Japanese patients with functional dyspepsia (FD): nizatidine improves clinical symptoms, gastric emptying and sleep disorders in FD patients. J Gastroenterol Hepatol 2013;28:1314-20.
  • 67 Futagami S., Shimpuku M., Yamawaki H., Izumi N., Kodaka Y., Nagoya H., Wakabayashi T., Shindo T., Kawagoe T., Sakamoto C. Sleep disorders in functional dyspepsia and future therapy. J Nippon Med Sch 2013;80:104-9.
  • 68 Futagami S., Shimpuku M., Kawagoe T., Izumi N., Ohishi N., Yamawaki H., Shindo T., Nagoya H., Horie A., Kodaka Y., Gudis K., Itoh T., Sakamoto C. The preproghrelin 3056 TT genotype is associated with the feeling of hunger and low acylated ghrelin levels in Japanese patients with Helicobacter pylori-negative functional dyspepsia. Intern Med 2013;52:1155-63.
  • 69 Fujimori S., Sakamoto C. Latest concepts on the association between nonsteroidal anti-inflammatory drug-induced small intestinal injury and intestinal bacterial flora. Clin J Gastroenterol 2013;6:345-51.
  • 70 Atsukawa M., Tsubota A., Shimada N., Kondo C., Itokawa N., Nakagawa A., Hashimoto S., Fukuda T., Matsushita Y., Kidokoro H., Narahara Y., Nakatsuka K., Iwakiri K., Kawamoto C., Sakamoto C. Efficacy of Alfacalcidol on PEG-IFN/ Ribavirin Combination Therapy for Elderly Patients With Chronic Hepatitis C: A Pilot Study. Hepat Mon 2013;13:e14872.
  • 71 Atsukawa M., Tsubota A., Kondo C., Itokawa N., Narahara Y., Nakatsuka K., Hashimoto S., Fukuda T., Matsushita Y., Kidokoro H., Kobayashi T., Kanazawa H., Sakamoto C. Combination of fluvastatin with pegylated interferon/ribavirin therapy reduces viral relapse in chronic hepatitis C infected with HCV genotype 1b. J Gastroenterol Hepatol 2013;28:51-6.
  • 72 Akimoto N., Fujimori T., Mitomi H., Ichikawa K., Tomita S., Tatsuguchi A., Fujimori S., Naito Z., Sakamoto C. Micropapillary pattern at the invasive front and its association with unresectable colorectal carcinomas. Dis Markers 2013;35:451-5.
  • 73 Takahashi Y., Fujimori S., Narahara Y., Gudis K., Ensaka Y., Kosugi Y., Maki K., Suzuki M., Matsushita Y., Fukuda T., Kanazawa H., Sakamoto C. Small intestinal edema had the strongest correlation with portal venous pressure amongst capsule endoscopy findings. Digestion 2012;86:48-54.
  • 74 Narahara Y., Kanazawa H., Sakamoto C., Maruyama H., Yokosuka O., Mochida S., Uemura M., Fukui H., Sumino Y., Matsuzaki Y., Masaki N., Kokubu S., Okita K. The efficacy and safety of terlipressin and albumin in patients with type 1 hepatorenal syndrome: a multicenter, open-label, explorative study. J Gastroenterol 2012;47:313-20.
  • 75 Kondo C., Atsukawa M., Tsubota A., Itokawa N., Fukuda T., Matsushita Y., Kidokoro H., Kobayashi T., Narahara Y., Nakatsuka K., Kanazawa H., Sakamoto C. An open-label randomized controlled study of pegylated interferon/ribavirin combination therapy for chronic hepatitis C with versus without fluvastatin. J Viral Hepat 2012;19:615-22.
  • 76 Kobayashi T., Nakatsuka K., Shimizu M., Tamura H., Shinya E., Atsukawa M., Harimoto H., Takahashi H., Sakamoto C. Ribavirin modulates the conversion of human CD4(+) CD25(-) T cell to CD4(+) CD25(+) FOXP3(+) T cell via suppressing interleukin-10-producing regulatory T cell. Immunology 2012;137:259-70.
  • 77 Futagami S., Shimpuku M., Song J. M., Kodaka Y., Yamawaki H., Nagoya H., Shindo T., Kawagoe T., Horie A., Gudis K., Iwakiri K., Sakamoto C. Nizatidine improves clinical symptoms and gastric emptying in patients with functional dyspepsia accompanied by impaired gastric emptying. Digestion 2012;86:114-21.
  • 78 Atsukawa M., Nakatsuka K., Kobayashi T., Shimizu M., Tamura H., Harimoto H., Takahashi H., Sakamoto C. Ribavirin downmodulates inducible costimulator on CD4+ T cells and their interleukin-10 secretion to assist in hepatitis C virus clearance. J Gastroenterol Hepatol 2012;27:823-31.

▲ページのトップに戻る

当科に関するお問い合わせは下記までお願いいたします。 日本医科大学 消化器内科学 〒113-8603東京都文京区千駄木1-1-5 TEL03-3822-2131(代表)

交通・地図はこちら